In 2025, the federal government made a decision that will reverberate for generations: awarding sixty-one percent fewer competitive grants to the National Institute on Minority Health and Health Disparities (NIMHD).
This drastic reduction is not a mere budgetary adjustment—it is a deliberate retreat from addressing the health inequities that have plagued Black and Brown communities for decades. And it is rooted in a divisive, false narrative that diversity, equity, and inclusion (DEI) policies are somehow antithetical to excellence in science.
Let’s be clear: DEI is not a political slogan. It is a framework for ensuring that research reflects the lived realities of all Americans, not just the privileged few. Yet, under the Trump Administration’s rhetoric—casting DEI as “woke ideology” and “illegal discrimination”—critical funding streams have been gutted. The result? Fewer resources to study conditions that disproportionately affect minority populations, such as Sickle Cell Disease, Black maternal mortality, hypertension, and diabetes. These are not abstract issues; they are matters of life and death.
Consider Sickle Cell Disease, a genetic disorder that primarily affects African Americans causing its patients to suffer severe discomfort in the arms, legs, chest, extreme fatigue, anemia, jaundice and swollen extremities. While breakthroughs in gene therapy offer hope, these treatments remain experimental and expensive. Continued research is essential to make them accessible and safe. Cutting grants means slowing progress—condemning thousands to unnecessary suffering.
Or take Black maternal health, which I have written about in this space highlighting racial bias in the delivery of healthcare and how it contributes to profound distrust of the medical establishment. The United States already has the highest maternal mortality rate among developed nations, and Black women are three to 3.5 times more likely to die from pregnancy-related complications than their White counterparts. These disparities stem from systemic racism, implicit bias in healthcare, and socioeconomic barriers. Without robust, targeted research, we cannot design interventions to save lives. These are preventable deaths. Reducing funding now is akin to the nation turning its back on mothers and babies who need these services the most.
Hypertension and cardiovascular disease tell a similar story. African Americans experience higher rates of both, leading to premature deaths and diminished quality of life. These conditions are influenced by complex interactions of genetics, environment, and social determinants of health. Cutting research dollars means fewer studies on culturally tailored interventions, fewer community-based programs, and ultimately, more preventable deaths.
The False Narrative Driving This Retreat
The justification for these cuts rests on a pernicious myth: that DEI initiatives dilute scientific rigor. Nothing could be further from the truth. Diversity in research teams and study populations enhances innovation and validity. When trials exclude minority participants, findings often fail to accurately reflect the broader population — leading to treatments that work well for some but not for all. DEI is not charity; it is a scientific necessity.
Yet, political rhetoric has weaponized the term, painting DEI as a partisan agenda rather than a public health imperative.
Under President Trump’s executive orders, federal agencies dismantled diversity programs, eliminated DEI offices, and revoked equity-related grants—framing inclusion efforts as discriminatory or “illegal”. This framing ignores decades of evidence showing that inclusive research saves lives. It also disregards the moral obligation of a government to serve all its citizens, not just those who fit a narrow demographic mold.
The origins of the NIMHD go back to 1990 and its forerunner the Office of Minority Programs housed inside the National Institutes of Health (NIH). It’s mission – to confront health disparities head-on — is not optional; it is foundational to a fair and effective healthcare system. Slashing its grant portfolio by more than half sends a chilling message that the health of minority communities is expendable. This is not just bad policy—it is dangerous governance.
And the ramifications of this kind of short-sighted, racially motivated decision-making will be profound. Young scientists committed to studying health equity will face dwindling opportunities, pushing talent out of the field. Community organizations that partner with researchers will lose vital support. And patients—real people with real needs—will pay the ultimate price.
Public health is not a partisan issue; it is a national priority. Lawmakers must restore funding to NIMHD and reaffirm the value of DEI in research. Philanthropic organizations and private sectors should step in to fill gaps, but they cannot replace the scale and stability of federal investment. Most importantly, we must challenge the false narratives that equate inclusion with mediocrity.
It’s a testament to how far we have regressed as a country that we have to even debate this issue. Science thrives on diversity—of thought, of experience, of perspective. The health of our nation depends on it.
David R. Jones, Esq., is President and CEO of the Community Service Society of New York (CSS), the leading voice on behalf of low-income New Yorkers for more than 175 years. The views expressed in this column are solely those of the writer. The Urban Agenda is available on CSS’s website: www.cssny.org.